Pharmacological approach to acute pancreatitis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 19

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

433

HTML

3568

Tables (1-2)

235

Sum=4236

May 21, 2008 (publication date) through Jan 19, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Practice Guidelines

World J Gastroenterol. May 21, 2008; 14(19): 2968-2976
Published online May 21, 2008. doi: 10.3748/wjg.14.2968

Table 2 Pharmacological prevention of PEP: Overview of drugs tested in clinical trials

Name	Mechanism	Incidence of PEP
Somatostatin	Inhibition of pancreatic secretion	No effect
Octreotid	Inhibition of pancreatic secretion	Probably reduced
Gabexate mesilate	Protease inhibitor	No effect
N-acetylcysteine	Reduction of oxidative stress	No effect
Nitrogen oxide	Improvement of micro-circulation	No effect
Steroids	Non-specific anti-inflammatory	No effect
Interleukin-10	Anti-inflammatory	Probably no effect
TNF-alpha	Specific anti-inflammatory	No published trials
Antibiotics	Antibacterial	Reduced

Citation: Bang UC, Semb S, Nøjgaard C, Bendtsen F. Pharmacological approach to acute pancreatitis. World J Gastroenterol 2008; 14(19): 2968-2976
URL: https://www.wjgnet.com/1007-9327/full/v14/i19/2968.htm
DOI: https://dx.doi.org/10.3748/wjg.14.2968